Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

Abstract

SummaryBackgroundThe global burden of disease attributable to respiratory syncytial virus (RSV) remains unknown. We aimed to estimate the global incidence of and mortality from episodes of acute lower respiratory infection (ALRI) due to RSV in children younger than 5 years in 2005.MethodsWe estimated the incidence of RSV-associated ALRI in children younger than 5 years, stratified by age, using data from a systematic review of studies published between January, 1995, and June, 2009, and ten unpublished population-based studies. We estimated possible boundaries for RSV-associated ALRI mortality by combining case fatality ratios with incidence estimates from hospital-based reports from published and unpublished studies and identifying studies with population-based data for RSV seasonality and monthly ALRI mortality.FindingsIn 2005, an estimated 33·8 (95% CI 19·3–46·2) million new episodes of RSV-associated ALRI occurred worldwide in children younger than 5 years (22% of ALRI episodes), with at least 3·4 (2·8–4·3) million episodes representing severe RSV-associated ALRI necessitating hospital admission. We estimated that 66 000–199 000 children younger than 5 years died from RSV-associated ALRI in 2005, with 99% of these deaths occurring in developing countries. Incidence and mortality can vary substantially from year to year in any one setting.InterpretationGlobally, RSV is the most common cause of childhood ALRI and a major cause of admission to hospital as a result of severe ALRI. Mortality data suggest that RSV is an important cause of death in childhood from ALRI, after pneumococcal pneumonia and Haemophilus influenzae type b. The development of novel prevention and treatment strategies should be accelerated as a priority.FundingWHO; Bill & Melinda Gates Foundation.

Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007‐2012

“…In older children and adults, RSV infection often leads to mild upper respiratory tract infection (URTI). However, in infants and young children, RSV is an important cause of severe respiratory infection, particularly bronchiolitis, which may require hospital admission 2. With a number of RSV vaccine candidates now in phase 2 and 3 clinical trials, it is essential to have accurate estimates of the hospital burden of RSV by age and risk group in order to determine the potential benefits of a future vaccine programme 3…”

Controlled human infection with RSV: The opportunities of experimental challenge

“…Respiratory syncytial virus (RSV) is the leading cause of infant respiratory tract infection in the world [1] and a major cause of morbidity and mortality in elderly adults [2]. Recent research has also added to a growing literature supporting a causal role for infant RSV infection in the development of wheeze and asthma in later life [3].…”

Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study

“…Respiratory syncytial virus (RSV) infection in childhood, particularly in premature infants, is associated with significant morbidity, hospitalization rates including neonatal intensive care unit admission, healthcare burden and mortality 1, 2, 3, 4. Infants in their first year of age are the most vulnerable population and globally 40% of RSV infections progress to lower respiratory tract infections (LRTI) 5, 6.…”